



## CERTIFICATE OF ANALYSIS No.: 2024-14356

## **CLIENT**

Pharmahemp d.o.o., Cesta v Gorice 8 1000 Ljubljana, Slovenija

SAMPLE \* DR KENT CBD CREAM FOR TIRED LEGS





Sample condition: Sample ID: Sample type: Batch No.: *	SUITABLE 2416012 Cream KCT01124200A	Work order: Analysis ID: Method ID: Method SOP:	D: 2024_135 : PHL_RPC_16C		Sample received: Start of analysis: End of analysis: Analyst:	16/04/2024 16/04/2024 17/04/2024 Valentina Malin
* Information provide	ed by the client.					
CANNABINOID PROFILE		Concentration [% w/w]		Expanded uncertainty [% w/w]	Graphic presentation of relative cannabinoid concentration	
CBDV - ca	annabidivarin	<loc< td=""><td>Ç</td><td>n/a</td><td></td><td></td></loc<>	Ç	n/a		
CBDA - C	annabidiolic acid	<l00< td=""><td>)</td><td>n/a</td><td></td><td></td></l00<>	)	n/a		

			•	
CBDV	- Cannabidivarin	<loq< td=""><td>n/a</td><td></td></loq<>	n/a	
CBDA	- Cannabidiolic acid	<loq< td=""><td>n/a</td><td></td></loq<>	n/a	
CBGA	- Cannabigerolic acid	<loq< td=""><td>n/a</td><td></td></loq<>	n/a	
CBG	- Cannabigerol	<loq< td=""><td>n/a</td><td></td></loq<>	n/a	
CBD	- Cannabidiol	1.091	0.055	
THCV	- Tetrahydrocannabivarin	<loq< td=""><td>n/a</td><td></td></loq<>	n/a	
CBN	- Cannabinol	<loq< td=""><td>n/a</td><td></td></loq<>	n/a	
$\Delta^9$ -THC	- Δ-9-Tetrahydrocannabinol	0.0418	0.0092	•
$\Delta^8$ -THC	- Δ-8-Tetrahydrocannabinol	<loq< td=""><td>n/a</td><td></td></loq<>	n/a	
CBL	- Cannabicyclol	<loq< td=""><td>n/a</td><td></td></loq<>	n/a	
CBC	- Cannabichromene	< LOQ	n/a	
Δ <sup>9</sup> -THC	A - Δ-9-Tetrahydrocannabinolic acid	< LOQ	n/a	
CBV	- Cannabivarin	<loq< td=""><td>n/a</td><td></td></loq<>	n/a	
CBCA	- Cannabichromenic acid	<loq< td=""><td>n/a</td><td></td></loq<>	n/a	
CBT	- Cannabicitran	<loq< td=""><td>n/a</td><td></td></loq<>	n/a	
CBE	- Cannabielsoin	< LOQ #	n/a	

Units and abbreviations: % w/w = weight percent, < LOQ = below the limit of quantitation (0.03 % w/w), ND = not detected, n/a = not available.

The results given herein apply only to the sample as received and tested. Expanded Uncertainty was calculated using coverage factor k = 2, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:	Approved by:	Authorized by:
17/04/2024	Aley	Janu Pote
	mag. Janja Ahej	dr. Boštjan Jančar
	Analytical Laboratory Manager	Chief Technology Officer
End of Certificate		